Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipients

Figures & data

TABLE 1.  Demographics of kidney transplant recipients

Characteristic	Study group I (n = 657)	Study group II (n = 798)	Control group (n = 76)	p
Gender
Male/female	343/314	427/371	45/31	ns
Mean age (years)	35.5	37.8	37.4	ns
Cadaveric graft (%)	99.7	99.6	100	ns
Mean warm ischemia (minutes)	7.5	7.4	7.7	ns
Mean cold ischemia (hours)	3.5	3.7	3.8	ns
Mean duration of dialysis	31.3	34.3	32.4	ns
HLA mismatch				ns
≤2	115 (17.5%)	127 (15.9%)	12 (15.8%)	ns
3–4	443 (67.4%)	534 (66.9%)	51 (67.1%)	ns
5–6	99 (15.1%)	137 (17.2%)	13 (17.1%)	ns
Panel reactive antibody				ns
≤10%	602 (91.6%)	737 (92.0%)	68 (89.5%)	ns
11–49%	33 (5.1%)	40 (5.0%)	4 (5.3%)	ns
≥50%	22 (3.3%)	24 (3.0%)	4 (5.2%)	ns

ns, no significance.

FIGURE 1.  Average oral CsA dose (mg/kg/d) and CsA serum levels (mg/L) at <1, 2–3, 4–6, 9–12, and >12 months posttransplantation in the study group I with a combination of diltiazem and a standard triple therapy [slightly reduced CsA (6.0 mg/kg/d), AZA, and prednisolone], in the study group II with a combination of diltiazem and a slightly different triple [reduced CsA (4.5–5.0 mg/kg/d), prednisolone, and mycophenelate mofetil] therapy, and in the control group with a standard triple therapy [normal CsA (8.0–9.0 mg/kg/d), AZA, and prednisolone].

FIGURE 2.  Patient (a) and graft (b) survival rates of kidney allograft recipients over 5-year follow-up. (a) shows the patient survival rates at 1-, 3-, and 5-year follow-up in the study group I, the study group II, and the control group; similarly (b) shows the corresponding graft survival rates at 1-, 3-, and 5-year follow-up in the three groups.

TABLE 2.  The occurrence rates of complications posttransplant in three groups

	Control group (n = 76)		Study group I (n = 657)		Study group II (n = 798)
	No.	%	No.	%	No.	%
Nephrotoxicity	14	18.4	71	10.8	53	6.6
Hepatotoxicity	22	28.9	131	19.9	98	12.3
Infection**
CMV	5	6.6	61	9.3	73	9.2
Pneumonia	7	7.9	33	5.0	39	4.9
UTI	10	10.5	104	15.8	141	17.7
EBV	2	2.6	26	4.0	28	3.5
Acute rejection	23	30.3	184	28.0	61	7.6

Notes: *p < 0.01, between control group vs. study group I;

**p > 0.05 among three groups.